Upstream's Trypanosomiasis Drug Candidates Found to Be Safe in Toxicity Tests
Posted on: Monday, 21 April 2008, 06:00 CDT
Upstream Biosciences has announced that the company's novel drug candidates to treat the parasitic disease trypanosomiasis have demonstrated good safety profiles in their first in vivo toxicity tests.
These toxicity studies in mice were conducted by trypanosomiasis researchers at Makerere University in Uganda. The Makerere researchers reported that Upstream's trypanosomiasis candidates were well tolerated by mice with no signs of serious toxicity at therapeutic dosages suggested by the in vitro experiments assessing the anti-malarial activity of these drug candidates.
Joel Bellenson, CEO of Upstream, said: "We look forward to advancing the preclinical program for these compounds that have the potential to significantly contribute to the health and economic vitality of this important region."
Source: Datamonitor
Related Articles
- Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening
- Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates
- Upstream Biosciences' Novel Agents to Treat Trypanosomiasis Demonstrate Promising Safety in Vivo
- Upstream Biosciences' Novel Agents to Treat Leishmaniasis Demonstrate Promising Safety Profile in Initial Toxicity Testing
- Upstream Biosciences to Collaborate With Moscow State University Chemists to Produce Drug Candidates for Tropical Parasitic Diseases
- SCYNEXIS and DNDi Enter Landmark Multi-Year Agreement to Identify Drug Candidates to Treat Sleeping Sickness
- Upstream Biosciences CEO to Unveil Promising New Approach to Treating Sleeping Sickness at International Trypanosomiasis Conference
- Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
- The Ecological Dynamics of Environmental Law and Policy
 |
 |
User Comments (0)
RSS Feeds